A Phase 2 interventional study of Gefitinib and AZD9291 in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV), sponsored by AstraZeneca. Completed at 10 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-08-02.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing gefitinib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. Gefitinib · Carcinoma, Non-Small-Cell Lung.
Among the 87 studies testing gefitinib in Carcinoma, Non-Small-Cell Lung, this one is the 65th largest by enrollment of the 84 interventional ones that give a count, is one of 6 that started in 2014, is one of 43 in phase 2, and was the 75th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 87 studies testing gefitinib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:
China Medical University Hospital · Sites in Taiwan
Ages 20–70
By country, each count listing its studies:
Gefitinib: first FDA approval 2003 (IRESSA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 52 · Phase 3 19 · Phase 4 3
First in 2000; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 65 across the 84 interventional studies. Of the 57 that completed or were terminated, 15 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 87 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 119th largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2014, is one of 38 in phase 2, and was the 62nd registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing gefitinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
Primary objective: To assess the efficacy of various sequences of either a small molecule or an IMT (IMT-A) followed by a IMT-B (MEDI4736) .
This is a multi-arm, multi-cohort, Phase IIa, open-label study of selected small molecules (gefitinib, AZD9291, or selumetinib + docetaxel) or 1st IMT (hereafter referred to as IMT-A; tremelimumab) followed by sequential switch to a 2nd IMT (hereafter referred to as IMT-B; MEDI4736) in locally advanced or metastatic NSCLC (Stage IIIB-IV). Patients will be enrolled concurrently into multiple cohorts.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gefitinib once daily followed by MEDI4736
Drug: Gefitinib
AZD9291 once daily followed by MEDI4736
Drug: AZD9291
Selumetinib twice daily + docetaxel, followed by MEDI4736
Drug: Selumetinib+Docetaxel
Tremelimumab every 4 weeks followed by MEDI4736
Drug: Tremelimumab
Gefitinib once daily followed by MEDI4736
AZD9291 once daily followed by MEDI4736
Drug pages: AZD 6244 · Docetaxel
Selumetinib twice daily + docetaxel, followed by MEDI4736
Tremelimumab every 4 weeks followed by MEDI4736
This study also gives Durvalumab. No intervention listed here names it: that was found by reading the record.
Confirmed Complete Response (CR) Rate
To assess the efficacy of various sequences. CR (per RECIST 1.1 as assessed by the local/site Investigator) is defined as the disappearance of all target and non-target lesions. Confirmed complete response rate (CR rate) is defined as the number (%) of patients with a confirmed overall response of CR and was based on the evaluable analysis set.
Time frame: Up to 2 years
Objective Response Rate (ORR)
To further assess the efficacy of various sequences. Objective response rate (ORR; per RECIST 1.1 as assessed by the site Investigator) is defined as the number (%) of patients with a confirmed overall response of CR or PR and was based on the evaluable analysis set. Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: Up to 2 years
Progression-free Survival
Progression-free survival (per RECIST 1.1 as assessed by Investigator) is defined as the date of 1st dose of MEDI4736 until the date of objective disease progression or death. Progression of disease (PD) At least a 20% increase in the sum of diameters of TLs, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Time frame: Up to 2 years
Duration of Response
Duration of response (DoR; per RECIST 1.1 as assessed by the site Investigator) will be defined as the time from the date of 1st documented response (which is subsequently confirmed) until the 1st date of documented progression or death in the absence of disease progression.
Time frame: Within 12 months
Overall Survival
To assess the efficacy of various sequences. In survival follow up at data cut off.
Time frame: Up to 2 years
This study was conducted at 10 study centers in United States. The first subject was enrolled on 25 July 2014.
| Milestone | Gefitinib With a Seq. Switch to a MEDI4736 | AZD9291 With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 |
|---|---|---|---|---|---|
| Started | 1 | 1 | 2 | 14 | 14 |
| Completed | 0 | 0 | 1 | 1 | 1 |
| Not completed | 1 | 1 | 1 | 13 | 13 |
To assess the efficacy of various sequences. CR (per RECIST 1.1 as assessed by the local/site Investigator) is defined as the disappearance of all target and non-target lesions. Confirmed complete response rate (CR rate) is defined as the number (%) of patients with a confirmed overall response of CR and was based on the evaluable analysis set.
| patients (%) | Gefitinib With a Seq. Switch to a MEDI4736 | AZD9291 With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 |
|---|---|---|---|---|---|
| Confirmed Complete Response (CR) Rate | — | — | — | 0 (NA to NA) | 0 (NA to NA) |
To further assess the efficacy of various sequences. Objective response rate (ORR; per RECIST 1.1 as assessed by the site Investigator) is defined as the number (%) of patients with a confirmed overall response of CR or PR and was based on the evaluable analysis set. Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| patients (%) | Gefitinib With a Seq. Switch to a MEDI4736 | AZD9291 With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | — | — | — | 11.1 (1.2 to 36.8) | 0 (NA to NA) |
Progression-free survival (per RECIST 1.1 as assessed by Investigator) is defined as the date of 1st dose of MEDI4736 until the date of objective disease progression or death. Progression of disease (PD) At least a 20% increase in the sum of diameters of TLs, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
| patients | Gefitinib With a Seq. Switch to a MEDI4736 | AZD9291 With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 |
|---|---|---|---|---|---|
| Progression-free Survival | — | — | — | 1 | 0 |
Duration of response (DoR; per RECIST 1.1 as assessed by the site Investigator) will be defined as the time from the date of 1st documented response (which is subsequently confirmed) until the 1st date of documented progression or death in the absence of disease progression.
| Months | Gefitinib With a Seq. Switch to a MEDI4736 | AZD9291 With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 |
|---|---|---|---|---|---|
| Duration of Response | — | — | — | NA | — |
To assess the efficacy of various sequences. In survival follow up at data cut off.
| patients | Gefitinib With a Seq. Switch to a MEDI4736 | AZD9291 With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 |
|---|---|---|---|---|---|
| Overall Survival | — | — | — | 0 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gefitinib With a Seq. Switch to a MEDI4736 | — | 0/1 (0%) | 1/1 (100%) |
| Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | — | 1/2 (50%) | 2/2 (100%) |
| AZD9291 With a Seq. Switch to MEDI4736 | — | — | — |
| Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | — | 5/14 (35.7%) | 13/14 (92.9%) |
| Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 | — | 8/13 (61.5%) | 13/13 (100%) |
| Event | Gefitinib With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | AZD9291 With a Seq. Switch to MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 |
|---|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/1 | 1/2 | — | 0/14 | 0/13 |
| DiverticulitisInfections and infestations | 0/1 | 1/2 | — | 0/14 | 0/13 |
| Enterocolitis infectiousInfections and infestations | 0/1 | 1/2 | — | 0/14 | 0/13 |
| DehydrationMetabolism and nutrition disorders | 0/1 | 0/2 | — | 0/14 | 2/13 |
| PneumoniaInfections and infestations | 0/1 | 0/2 | — | 2/14 | 1/13 |
| Acute myocardial infarctionCardiac disorders | 0/1 | 0/2 | — | 0/14 | 1/13 |
| Cardiac arrestCardiac disorders | 0/1 | 0/2 | — | 0/14 | 1/13 |
| Pericardial effusionCardiac disorders | 0/1 | 0/2 | — | 0/14 | 1/13 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/1 | 0/2 | — | 0/14 | 1/13 |
| NauseaGastrointestinal disorders | 0/1 | 0/2 | — | 0/14 | 1/13 |
| Event | Gefitinib With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | AZD9291 With a Seq. Switch to MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 |
|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/1 | 2/2 | — | 3/14 | 2/13 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 2/2 | — | 6/14 | 3/13 |
| DyspepsiaGastrointestinal disorders | 0/1 | 2/2 | — | 1/14 | 0/13 |
| VomitingGastrointestinal disorders | 0/1 | 2/2 | — | 4/14 | 3/13 |
| FatigueGeneral disorders | 1/1 | 1/2 | — | 6/14 | 5/13 |
| Upper respiratory tract infectionInfections and infestations | 1/1 | 0/2 | — | 0/14 | 0/13 |
| Urinary tract infectionInfections and infestations | 1/1 | 0/2 | — | 2/14 | 1/13 |
| HypomagnesaemiaMetabolism and nutrition disorders | 1/1 | 0/2 | — | 0/14 | 2/13 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/1 | 2/2 | — | 0/14 | 0/13 |
| HaematuriaRenal and urinary disorders | 1/1 | 0/2 | — | 1/14 | 0/13 |
The 1 patient in the AZD9291 cohort was not dosed and no baseline data were recorded in the database. Because the AZD9291 with a Seq. Switch to a MEDI4736 arm had no data recorded during the study, this arm is not included in the reporting of adverse events.
| Age, Continuous(Years) | Gefitinib With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 | AZD9291 With a Seq. Switch to a MEDI4736 | Total |
|---|---|---|---|---|---|---|
| Mean | 79.0 ± 0 | 65.0 ± 12.73 | 57.8 ± 12.05 | 64.3 ± 7.85 | — | 61.8 ± 10.85 |
| Sex: Female, Male(Participants) | Gefitinib With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 | AZD9291 With a Seq. Switch to a MEDI4736 | Total |
|---|---|---|---|---|---|---|
| Female | 0 | 1 | 6 | 4 | — | 11 |
| Male | 1 | 1 | 8 | 9 | — | 19 |
| Race/Ethnicity, Customized(Participants) | Gefitinib With a Seq. Switch to a MEDI4736 | Selumetinib+Docetaxel With a Seq. Switch to a MEDI4736 | Tremelimumab (1 Cycle) With a Seq. Switch to a MEDI4736 | Tremelimumab (2 Cycles) With a Seq. Switch to MEDI4736 | AZD9291 With a Seq. Switch to a MEDI4736 | Total |
|---|---|---|---|---|---|---|
| White | 1 | 2 | 12 | 11 | — | 23 |
| Black or African American | 0 | 0 | 2 | 2 | — | 4 |
Ran from Jul 2014 to primary completion in Jun 2016, 22 months.
Results were first posted in Aug 2019, 3 years 1 month after primary completion.
Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 22 months is below that.
Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Gefitinib · Osimertinib · AZD 6244 · Docetaxel · Tremelimumab · Durvalumab
Carcinoma, Non-Small-Cell Lung →